Neuroplast is a clinical stage biotechnology company that develops the autologous stem cell platform product Neuro-Cells®, a first-in-kind treatment to combat neurodegeneration resulting from trauma, disease and ageing. Neuroplast was founded in 2017 to develop this disruptive autologous cell therapy to combat spinal cord injury related neurodegeneration.
 

Neurodegenerative conditions seem diverse in phenotype, but they share a common degenerative pathway at cellular level. The living autologous cell therapy Neuro-Cells® targets these common pathways. 
 

Neuroplast holds two European Orphan Disease Designations for spinal cord injury and frontotemporal dementia. With increasing evidence for broader applications. Neuro-Cells® addresses a multi-billion market and offers a treatment perspective for millions of people for whom no treatment exists today